Prima BioMed and Neopharm Group Execute Final Agreement for CVac License

[Marketwired] – Prima BioMed Ltd is pleased to announce that it has finalized an agreement with Neopharm Group for an exclusive license to market and sell CVacâ„¢, a personalized immunocellular therapeutic under investigation … more

View todays social media effects on PBMD

View the latest stocks trending across Twitter. Click to view dashboard

See who Prima is hiring next, click here to view